Journal
CNS SPECTRUMS
Volume 19, Issue 2, Pages 142-156Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852913000771
Keywords
Clinical trials; cognitive deficits; MATRICS; pharmacotherapy; schizophrenia
Categories
Funding
- Dainippon Sumitomo Pharma
Ask authors/readers for more resources
While second-generation antipsychotics treat negative as well as positive symptoms, recovery for persons with schizophrenia remains elusive, in part because there are no FDA-approved medications that treat the cognitive deficits of schizophrenia (CDS). Recent work has identified agents that, when added to antipsychotics, improve cognition in schizophrenia. This work and hypothesized mechanisms of action will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available